Note 9 - Commitments	3 Months Ended
Mar. 31, 2024
Notes to Financial Statements
Leases And Commitments Disclosure [Text Block]	Note 9. Commitments Right-of-use Asset and Liability The Company had an operating lease for approximately 6,000 square feet of office space in Austin, Texas with an expiration of April 30, 2024. The Company and the landlord consented to early terminate this lease on February 22, 2023 with no continuing obligations. There was no rent expense for the three months ended March 31, 2024. Rent expense for the three months ended March 31, 2023 totaled $24,000. There was no cash paid for operating lease liabilities during the three months ended March 31, 2024. Cash paid for operating lease liabilities during the three months ended March 31, 2023 totaled $24,000. Other Commitments The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations that are cancelable. The Company’s obligations under these contracts are largely based on services performed.

Note 9 - Commitments

3 Months Ended

Mar. 31, 2024

Leases And Commitments Disclosure [Text Block]

Note 9. Commitments

Right-of-use Asset and Liability

The Company had an operating lease for approximately 6,000 square feet of office space in Austin, Texas with an expiration of April 30, 2024. The Company and the landlord consented to early terminate this lease on February 22, 2023 with no continuing obligations.

There was no rent expense for the three months ended March 31, 2024. Rent expense for the three months ended March 31, 2023 totaled $24,000.

There was no cash paid for operating lease liabilities during the three months ended March 31, 2024. Cash paid for operating lease liabilities during the three months ended March 31, 2023 totaled $24,000.

Other Commitments

The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations that are cancelable. The Company’s obligations under these contracts are largely based on services performed.